CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Retirement of Directors
On May 5, 2017, Anita J. Chawla, Ph.D., and Eric J. Selter, respectively, informed CytRx Corporation (“we,” “us,” “our” or the “company”) of their decisions to retire for personal reasons as directors of the Company, effective immediately prior to our upcoming Annual Meeting of Stockholders expected to be held on or about July 12, 2017.
Appointment of Director
At a meeting held on May 5, 2017, our board of directors appointed Joel Caldwell to replace Mr. Selter as a Class III director and as Chairman of the Audit Committee of our board of directors as of the date of our Annual Meeting of Stockholders.
Mr. Caldwell, age 62, brings more than 30 years of experience in tax matters, finance and internal auditing. He retired from Southern California Edison, one of the nation’s largest public utilities, where he had been employed for 28 years in various executive-level accounting and finance positions covering Internal Audits, Executive Compensation, Long Term Finance, Employee Benefits and, most recently prior to his retirement, Sarbanes-Oxley Internal Controls Compliance. He also worked in public accounting at the firm of Arthur Andersen & Co. Mr. Caldwell volunteers his business skills, serving as a financial advisor on the board of trustees of a charitable organization, and continues his involvement with track and field sports by volunteering as a meet official at Pacific Palisades Charter High School. Mr. Caldwell holds B.S. and M.B.A. degrees from the University of California, Berkeley. He has been a Certified Public Accountant in California since 1982 and a Certified Internal Auditor since 1986. Mr. Caldwell is a member of both the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants.
Mr. Caldwell will be compensated for his services as a director and Chairman of the Audit Committee in accordance with our usual policies. In connection with the effectiveness of his appointment, it is expected that Mr. Caldwell will be granted under our 2008 Stock Incentive Plan an immediately vested non-qualified stock option to purchase up to 180,000 shares of our common stock at an exercise price equal to the market price of our common stock on the date of grant.
###


About CYTRX CORPORATION (NASDAQ:CYTR)

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

CYTRX CORPORATION (NASDAQ:CYTR) Recent Trading Information

CYTRX CORPORATION (NASDAQ:CYTR) closed its last trading session down -0.030 at 0.436 with 5,668,083 shares trading hands.